By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ViaCyte, Inc. (Formerly Known as Novocell, Inc.) 

3550 General Atomics Court
Building 2, Room 503
San Diego  California  92121  U.S.A.
Phone: 858-455-3708 Fax: 858-455-3962


Company News
ViaCyte Announces First Patients Implanted With PEC-Direct Islet Cell Replacement Therapy In International Clinical Trial 8/1/2017 12:43:18 PM
JDRF And ViaCyte Announce Support For Development Of PEC-Direct Cell Replacement Therapy For Type 1 Diabetes 5/22/2017 10:30:58 AM
ViaCyte Announces $10 Million In Financing 5/22/2017 9:06:09 AM
ViaCyte Receives IND Allowance From FDA And Clearance From Health Canada To Commence International Clinical Trial Of PEC-Direct Cell Therapy For High-Risk Type 1 Diabetes 5/22/2017 7:34:48 AM
ViaCyte And W. L. Gore & Associates Announce Collaborative Research Agreement To Develop Novel Implantable Delivery Technologies For Cell Therapies 3/29/2017 8:27:54 AM
Beyond Type 1 Provides Grant To ViaCyte To Support Research And Development Of Cell Replacement Therapies For Type 1 Diabetes 2/23/2017 7:41:02 AM
Twenty-two New Patents Are Added To ViaCyte's Intellectual Property Portfolio 1/4/2017 7:24:29 AM
ViaCyte To Present At Healthcare Events In October 10/11/2016 10:33:20 AM
ViaCyte To Provide A Corporate Update At 2016 Cell And Gene Meeting On The Mesa 10/4/2016 9:59:08 AM
ViaCyte To Speak On Diabetes Panel At BioPharm America 2016 9/12/2016 10:20:27 AM